```
     FILE 'REGISTRY' ENTERED AT 13:22:47 ON 31 JUL 2008
L7                STRUCTURE UPLOADED
L8                STRUCTURE UPLOADED
L9                STRUCTURE UPLOADED
L10               STRUCTURE UPLOADED
L11             1 S L10
L12            22 S L10 SSS FULL

     FILE 'CAPLUS' ENTERED AT 13:52:40 ON 31 JUL 2008
L13             5 S L12

     FILE 'REGISTRY' ENTERED AT 14:02:04 ON 31 JUL 2008
L14               STRUCTURE UPLOADED
L15             0 S L14
L16             0 S L14 SSS FULL
```

PASSWORD:
 * * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'REGISTRY' AT 13:51:21 ON 31 JUL 2008
FILE 'REGISTRY' ENTERED AT 13:51:21 ON 31 JUL 2008

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	2.30	213.12

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-8.00

=>
Uploading C:\Program Files\STNEXP\Queries\10780447linker.str



chain nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44
45 46
chain bonds :
1-2 1-3 1-4 2-5 3-6 4-7 5-14 6-11 7-8 8-9 9-10 10-19 10-20 11-12 12-13
13-18 13-21 14-15 15-16 16-17 16-22 17-23 17-45 18-25 18-46 19-27 19-41
23-24 24-31
25-26 26-30 27-28 28-29 29-34 29-42 30-33 30-43 31-32 31-44 32-37 32-40
33-36 33-39
34-35 34-38
exact/norm bonds :
10-19 10-20 13-18 13-21 16-17 16-22 29-34 30-33 31-32 32-37 33-36 34-35

exact bonds :
1-2 1-3 1-4 2-5 3-6 4-7 5-14 6-11 7-8 8-9 9-10 11-12 12-13 14-15 15-16
17-23 17-45 18-25 18-46 19-27 19-41 23-24 24-31 25-26 26-30 27-28 28-29
29-42 30-43
31-44 32-40 33-39 34-38

```
Match level :
1:CLASS  2:CLASS  3:CLASS  4:CLASS  5:CLASS  6:CLASS  7:CLASS  8:CLASS  9:CLASS
10:CLASS  11:CLASS  12:CLASS  13:CLASS  14:CLASS  15:CLASS  16:CLASS  17:CLASS
18:CLASS  19:CLASS
20:CLASS  21:CLASS  22:CLASS  23:CLASS  24:CLASS  25:CLASS  26:CLASS  27:CLASS
28:CLASS  29:CLASS
30:CLASS  31:CLASS  32:CLASS  33:CLASS  34:CLASS  35:CLASS  36:CLASS  37:CLASS
38:CLASS  39:CLASS
40:CLASS  41:CLASS  42:CLASS  43:CLASS  44:CLASS  45:CLASS  46:CLASS



L10     STRUCTURE UPLOADED

=> s l10
SAMPLE SEARCH INITIATED 13:51:46 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      901 TO ITERATE

100.0% PROCESSED      901 ITERATIONS                              1 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        16220 TO    19820
PROJECTED ANSWERS:               1 TO       80

L11           1 SEA SSS SAM L10

=> d l11 scan

L11  1 ANSWERS   REGISTRY  COPYRIGHT 2008 ACS on STN
IN   Gadolinium, aqua[6,9-bis[(carboxy-κO)methyl]-21-[(4-O-β-D-
     galactopyranosyl-D-gluconoyl)amino]-3-[2-[[2-[3-[[2-[(4-O-β-D-
     galactopyranosyl-D-gluconoyl)amino]ethyl]amino]-3-oxopropoxy]-1,1-bis[[3-
     [[2-[(4-O-β-D-galactopyranosyl-D-gluconoyl)amino]ethyl]amino]-3-
     oxopropoxy]methyl]ethyl]amino]-2-(oxo-κO)ethyl]-13,13-bis[[3-[[2-[(4-
     O-β-D-galactopyranosyl-D-gluconoyl)amino]ethyl]amino]-3-
     oxopropoxy]methyl]-11-(oxo-κO)-18-oxo-15-oxa-3,6,9,12,19-
     pentaazaheneicosanoato(3-)-κN3,κN6,κN9,κO1]-
MF   C124 H220 Gd N17 O87
CI   CCS
```

PAGE 1-B



PAGE 2-A



PAGE 2-B



PAGE 2-C



PAGE 3-A

O=

PAGE 3-B



PAGE 4-A

HO—

HO—

HO—CH2—

PAGE 4-B



PAGE 5-A



PAGE 5-B



PAGE 6-B



PAGE 7-A

HO———

PAGE 7-B



ALL ANSWERS HAVE BEEN SCANNED

=> 0
0 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> 0
0 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s l10 sss full
FULL SEARCH INITIATED 13:52:35 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 17973 TO ITERATE

100.0% PROCESSED 17973 ITERATIONS 22 ANSWERS
SEARCH TIME: 00.00.01

L12 22 SEA SSS FUL L10

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	181.12	391.94

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE ENTRY TOTAL SESSION
CA SUBSCRIBER PRICE 0.00 -8.00

FILE 'CAPLUS' ENTERED AT 13:52:40 ON 31 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 31 Jul 2008 VOL 149 ISS 5
FILE LAST UPDATED: 30 Jul 2008 (20080730/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> s l12
L13 5 L12

=> d l13 1-5 ti abs bib hitstr

L13 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
TI Preparation of monosaccharide- and oligosaccharide-containing gadolinium compounds and contrast medium for MRI
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Gadolinium compds. represented by the following general formula (I) [R = (G1-NHCH2CH2)2N, [(G2-NHCH2CH2)2NCOCH2CH2OCH2]3C; G1 or G2 represents a residue formed by reacting a sugar lactone with an amino group, the sugar of the sugar lactone representing allose, altrose, mannose, gulose, idose, galactose, talose, ribose, arabinose, xylose, lyxose, erythrose, threose, cellobiose, maltose, lactose, or maltotriose], are prepared The novel gadolinium compds. (1) have a high spin-lattice relaxation (T1) property and can form an image with high sensitivity even when administered in a small amount, (2) are highly effective in imaging systemic blood vessels and the liver, (3) are highly effective in imaging the pancreas, and (4) have such safety that most of the compound is discharged from the body within 24 h. There is also provided a MRI contrast medium containing the compound I. Thus, ring-opening amidation of allonolactone with diethylenetriamine in DMF at room temperature followed by N-protection with di(tert-butyl) dicarbonate

in DMF, acetylation of the sugar moiety with acetic anhydride in pyridine, and removing the Boc group with CF3CO2H in CH2Cl2 at room temperature gave the amide (Q3-H; R1 = Ac) which underwent amidation with 2-[N,N-bis[2-(2,6-dioxomorpholin-4-yl)ethyl]amino]acetic acid (DTPA dianhydride) in DMF to give the amide (II; R1 = Ac). II was heated with Gd2O3 in H2O at 100° followed by treatment with 1 M aqueous NaOH solution at 40° to give allonamide-containing DTPA-gadolinium complex I (R = Q3; R1 = H) which showed 1/T1 of 40.5 s-1.

AN 2008:473521 CAPLUS <<LOGINID::20080731>>

DN 148:485896

TI Preparation of monosaccharide- and oligosaccharide-containing gadolinium compounds and contrast medium for MRI

IN Miura, Norio; Yamashita, Mitsuji

PA National University Corporation Shizuoka University, Japan; Konica Minolta Holdings, Inc.

SO PCT Int. Appl., 121pp.
CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008044443	A1	20080417	WO 2007-JP68298	20070920

PI WO 2008044443 A1 20080417

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI JP 2006-274710 A 20061006

OS MARPAT 148:485896

IT 1020112-53-1P 1020112-54-2P 1020112-55-3P
1020112-56-4P 1020213-18-6P 1020213-19-7P
1020213-20-0P 1020213-21-1P 1020213-22-2P
1020213-23-3P 1020213-24-4P 1020213-25-5P
1020213-26-6P 1020213-27-7P 1020213-29-9P
1020213-30-2P
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of monosaccharide- and oligosaccharide-containing gadolinium DTPA
compds. and contrast media containing them for MRI)

RN 1020112-53-1 CAPLUS

CN Gadolinium, [21-(D-allonoylamino)-3-[2-[[2-[3-[[2-(D-allonoylamino)ethyl]amino]-3-oxopropoxy]-1,1-bis[[3-[[2-(D-allonoylamino)ethyl]amino]-3-oxopropoxy]methyl]ethyl]amino]-2-(oxo-κO)ethyl]-13,13-bis[[3-[[2-(D-allonoylamino)ethyl]amino]-3-oxopropoxy]methyl]-11-(oxo-κO)-18-oxo-15-oxa-3,6,9,12,19-pentaazaheneicosanoato(3-)-κN3,κN6,κN9,κO1]aqua-
(CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 2-A





RN 1020112-54-2 CAPLUS
CN Gadolinium, aqua[6,9-bis[(carboxy-κO)methyl]-11-(oxo-κO)-18-oxo-3-[2-(oxo-κO)-2-[[2-[3-oxo-3-[[2-(D-ribonoylamino)ethyl]amino]propoxy]-1,1-bis[[3-oxo-3-[[2-(D-ribonoylamino)ethyl]amino]propoxy]methyl]ethyl]amino]ethyl]-13,13-bis[[3-oxo-3-[[2-(D-ribonoylamino)ethyl]amino]propoxy]methyl]-21-(D-ribonoylamino)-15-oxa-3,6,9,12,19-pentaazaheneicosanoato(3-)-κN3,κN6,κN9,κO1]- (CA INDEX NAME)



PAGE 1-B



PAGE 1-C



PAGE 2-A



PAGE 2-B



RN 1020112-55-3 CAPLUS
CN Gadolinium, aqua[24,25,26-trihydroxy-11-(oxo-κO)-18,23-dioxo-3-[15,16,17-trihydroxy-2-(oxo-κO)-9,14-dioxo-13,13-bis[[3-oxo-3-[[2-[(2,3,4-trihydroxy-1-oxobutyl)amino]ethyl]amino]propoxy]methyl]-4,4-bis[[3-oxo-3-[[2-[(2,3,4-trihydroxy-1-oxobutyl)amino]ethyl]amino]propoxy]methyl]-6-oxa-3,10,13-triazaheptadec-1-yl]-15-oxa-3,6,9,12,19,22-hexaazahexacosanoato(3-)-κN3,κN6,κN9,κO1]- (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 2-A





RN 1020112-56-4 CAPLUS

CN Gadolinium, aqua[6,9-bis[(carboxy-κO)methyl]-21-[(4-O-β-D-glucopyranosyl-D-gluconoyl)amino]-3-[2-[[2-[3-[[2-[(4-O-β-D-glucopyranosyl-D-gluconoyl)amino]ethyl]amino]-3-oxopropoxy]-1,1-bis[[3-[[2-[(4-O-β-D-glucopyranosyl-D-gluconoyl)amino]ethyl]amino]-3-oxopropoxy]methyl]ethyl]amino]-2-(oxo-κO)ethyl]-13,13-bis[[3-[[2-[(4-O-β-D-glucopyranosyl-D-gluconoyl)amino]ethyl]amino]-3-oxopropoxy]methyl]-11-(oxo-κO)-18-oxo-15-oxa-3,6,9,12,19-pentaazaheneicosanoato(3-)-κN3,κN6,κN9,κO1]- (CA INDEX NAME)

PAGE 1-B



PAGE 2-A



PAGE 2-B



PAGE 2-C



PAGE 3-A

O=

PAGE 3-B



PAGE 4-A

HO—

HO—

HO—CH2—

PAGE 4-B



PAGE 5-A



PAGE 5-B



PAGE 6-B



PAGE 7-A

HO———

PAGE 7-B



RN 1020213-18-6 CAPLUS
CN Gadolinium, [21-(D-altronoylamino)-3-[2-[[2-[3-[[2-(D-altronoylamino)ethyl]amino]-3-oxopropoxy]-1,1-bis[[3-[[2-(D-altronoylamino)ethyl]amino]-3-oxopropoxy]methyl]ethyl]amino]-2-(oxo-κO)ethyl]-13,13-bis[[3-[[2-(D-altronoylamino)ethyl]amino]-3-oxopropoxy]methyl]-6,9-bis[(carboxy-κO)methyl]-11-(oxo-κO)-18-oxo-15-oxa-3,6,9,12,19-pentaazaheneicosanoato(3-)-κN3,κN6,κN9,κO1]aqua- (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 2-A



PAGE 2-B



RN 1020213-19-7 CAPLUS

CN Gadolinium, aqua[6,9-bis[(carboxy-κO)methyl]-21-(D-gluconoylamino)-3-[2-[[2-[3-[[2-(D-gluconoylamino)ethyl]amino]-3-oxopropoxy]-1,1-bis[[3-[[2-(D-gluconoylamino)ethyl]amino]-3-oxopropoxy]methyl]ethyl]amino]-2-(oxo-κO)ethyl]-13,13-bis[[3-[[2-(D-gluconoylamino)ethyl]amino]-3-oxopropoxy]methyl]-11-(oxo-κO)-18-oxo-15-oxa-3,6,9,12,19-pentaazaheneicosanoato(3-)-κN3,κN6,κN9,κO1]- (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 2-A





RN 1020213-20-0 CAPLUS
CN Gadolinium, aqua[6,9-bis[(carboxy-κO)methyl]-21-(D-mannonoylamino)-3-[2-[[2-[3-[[2-(D-mannonoylamino)ethyl]amino]-3-oxopropoxy]-1,1-bis[[3-[[2-(D-mannonoylamino)ethyl]amino]-3-oxopropoxy]methyl]ethyl]amino]-2-(oxo-κO)ethyl]-13,13-bis[[3-[[2-(D-mannonoylamino)ethyl]amino]-3-oxopropoxy]methyl]-11-(oxo-κO)-18-oxo-15-oxa-3,6,9,12,19-pentaazaheneicosanoato(3-)-κN3,κN6,κN9,κO1]- (CA INDEX NAME)



PAGE 1-B



PAGE 1-C



PAGE 2-A



PAGE 2-B



RN 1020213-21-1 CAPLUS

CN Gadolinium, aqua[6,9-bis[(carboxy-κO)methyl]-21-(D-gulonoylamino)-3-[2-[[2-[3-[[2-(D-gulonoylamino)ethyl]amino]-3-oxopropoxy]-1,1-bis[[3-[[2-(D-gulonoylamino)ethyl]amino]-3-oxopropoxy]methyl]ethyl]amino]-2-(oxo-κO)ethyl]-13,13-bis[[3-[[2-(D-gulonoylamino)ethyl]amino]-3-oxopropoxy]methyl]-11-(oxo-κO)-18-oxo-15-oxa-3,6,9,12,19-pentaazaheneicosanoato(3-)-κN3,κN6,κN9,κO1]- (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 2-A





RN 1020213-22-2 CAPLUS

CN Gadolinium, aqua[6,9-bis[(carboxy-κO)methyl]-21-(D-idonoylamino)-3-[2-[[2-[3-[[2-(D-idonoylamino)ethyl]amino]-3-oxopropoxy]-1,1-bis[[3-[[2-(D-idonoylamino)ethyl]amino]-3-oxopropoxy]methyl]ethyl]amino]-2-(oxo-κO)ethyl]-13,13-bis[[3-[[2-(D-idonoylamino)ethyl]amino]-3-oxopropoxy]methyl]-11-(oxo-κO)-18-oxo-15-oxa-3,6,9,12,19-pentaazaheneicosanoato(3-)-κN3,κN6,κN9,κO1]- (CA INDEX NAME)



PAGE 1-B



PAGE 1-C



PAGE 2-A



PAGE 2-B



RN 1020213-23-3 CAPLUS

CN Gadolinium, aqua[6,9-bis[(carboxy-κO)methyl]-21-(D-galactonoylamino)-3-[2-[[2-[3-[[2-(D-galactonoylamino)ethyl]amino]-3-oxopropoxy]-1,1-bis[[3-[[2-(D-galactonoylamino)ethyl]amino]-3-oxopropoxy]methyl]ethyl]amino]-2-(oxo-κO)ethyl]-13,13-bis[[3-[[2-(D-galactonoylamino)ethyl]amino]-3-oxopropoxy]methyl]-11-(oxo-κO)-18-oxo-15-oxa-3,6,9,12,19-pentaazaheneicosanoato(3-)-κN3,κN6,κN9,κO1]- (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 2-A





RN 1020213-24-4 CAPLUS
CN Gadolinium, aqua[6,9-bis[(carboxy-κO)methyl]-11-(oxo-κO)-18-oxo-3-[2-(oxo-κO)-2-[[2-[3-oxo-3-[[2-(D-talonoylamino)ethyl]amino]propoxy]-1,1-bis[[3-oxo-3-[[2-(D-talonoylamino)ethyl]amino]propoxy]methyl]ethyl]amino]ethyl]-13,13-bis[[3-oxo-3-[[2-(D-talonoylamino)ethyl]amino]propoxy]methyl]-21-(D-talonoylamino)-15-oxa-3,6,9,12,19-pentaazaheneicosanoato(3-)-κN3,κN6,κN9,κO1]- (CA INDEX NAME)



PAGE 1-B



PAGE 1-C



PAGE 2-A



PAGE 2-B



RN 1020213-25-5 CAPLUS

CN Gadolinium, aqua[21-(D-arabinonoylamino)-3-[2-[[2-[3-[[2-(D-arabinonoylamino)ethyl]amino]-3-oxopropoxy]-1,1-bis[[3-[[2-(D-arabinonoylamino)ethyl]amino]-3-oxopropoxy]methyl]ethyl]amino]-2-(oxo-κO)ethyl]-13,13-bis[[3-[[2-(D-arabinonoylamino)ethyl]amino]-3-oxopropoxy]methyl]-6,9-bis[(carboxy-κO)methyl]-11-(oxo-κO)-18-oxo-15-oxa-3,6,9,12,19-pentaazaheneicosanoato(3-)-κN3,κN6,κN9,κO1]- (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 2-A





RN 1020213-26-6 CAPLUS
CN Gadolinium, aqua[6,9-bis[(carboxy-κO)methyl]-11-(oxo-κO)-18-oxo-3-[2-(oxo-κO)-2-[[2-[3-oxo-3-[[2-(D-xylonoylamino)ethyl]amino]propoxy]-1,1-bis[[3-oxo-3-[[2-(D-xylonoylamino)ethyl]amino]propoxy]methyl]ethyl]amino]ethyl]-13,13-bis[[3-oxo-3-[[2-(D-xylonoylamino)ethyl]amino]propoxy]methyl]-21-(D-xylonoylamino)-15-oxa-3,6,9,12,19-pentaazaheneicosanoato(3-)-κN3,κN6,κN9,κO1]- (CA INDEX NAME)



PAGE 1-B



PAGE 1-C



PAGE 2-A



PAGE 2-B



RN 1020213-27-7 CAPLUS
CN Gadolinium, aqua[6,9-bis[(carboxy-κO)methyl]-21-(D-lyxonoylamino)-3-[2-[[2-[3-[[2-(D-lyxonoylamino)ethyl]amino]-3-oxopropoxy]-1,1-bis[[3-[[2-(D-lyxonoylamino)ethyl]amino]-3-oxopropoxy]methyl]ethyl]amino]-2-(oxo-κO)ethyl]-13,13-bis[[3-[[2-(D-lyxonoylamino)ethyl]amino]-3-oxopropoxy]methyl]-11-(oxo-κO)-18-oxo-15-oxa-3,6,9,12,19-pentaazaheneicosanoato(3-)-κN3,κN6,κN9,κO1]- (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 2-A





RN 1020213-29-9 CAPLUS

CN Gadolinium, aqua[6,9-bis[(carboxy-κO)methyl]-21-[(4-O-α-D-glucopyranosyl-D-gluconoyl)amino]-3-[2-[[2-[3-[[2-[(4-O-α-D-glucopyranosyl-D-gluconoyl)amino]ethyl]amino]-3-oxopropoxy]-1,1-bis[[3-[[2-[(4-O-α-D-glucopyranosyl-D-gluconoyl)amino]ethyl]amino]-3-oxopropoxy]methyl]ethyl]amino]-2-(oxo-κO)ethyl]-13,13-bis[[3-[[2-[(4-O-α-D-glucopyranosyl-D-gluconoyl)amino]ethyl]amino]-3-oxopropoxy]methyl]-11-(oxo-κO)-18-oxo-15-oxa-3,6,9,12,19-pentaazaheneicosanoato(3-)-κN3,κN6,κN9,κO1]- (CA INDEX NAME)

PAGE 1-B



PAGE 2-A



PAGE 2-B



PAGE 2-C



PAGE 3-A

O=

PAGE 3-B



PAGE 4-A

HO—

HO—

HO—CH2—

PAGE 4-B



PAGE 5-A



PAGE 5-B



PAGE 6-B



PAGE 7-A

HO———

PAGE 7-B



RN 1020213-30-2 CAPLUS

CN Gadolinium, aqua[6,9-bis[(carboxy-κO)methyl]-21-[(4-O-β-D-galactopyranosyl-D-gluconoyl)amino]-3-[2-[[2-[3-[[2-[(4-O-β-D-galactopyranosyl-D-gluconoyl)amino]ethyl]amino]-3-oxopropoxy]-1,1-bis[[3-[[2-[(4-O-β-D-galactopyranosyl-D-gluconoyl)amino]ethyl]amino]-3-oxopropoxy]methyl]ethyl]amino]-2-(oxo-κO)ethyl]-13,13-bis[[3-[[2-[(4-O-β-D-galactopyranosyl-D-gluconoyl)amino]ethyl]amino]-3-oxopropoxy]methyl]-11-(oxo-κO)-18-oxo-15-oxa-3,6,9,12,19-pentaazaheneicosanoato(3-)-κN3,κN6,κN9,κO1]- (CA INDEX NAME)

PAGE 1-B



PAGE 2-A



PAGE 2-B



PAGE 2-C



PAGE 3-A

O=

PAGE 3-B



PAGE 4-A

HO—

HO—

HO—CH2—

PAGE 4-B



PAGE 5-A



PAGE 5-B



PAGE 6-B



PAGE 7-A

HO——

PAGE 7-B



IT 1020112-70-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of monosaccharide- and oligosaccharide-containing gadolinium DTPA
compds. and contrast media containing them for MRI)
RN 1020112-70-2 CAPLUS
CN D-Allonamide, N,N'-[9-amino-4,14-dioxo-9-[[3-oxo-3-[[2-[(2,3,4,5,6-penta-O-acetyl-D-allonoyl)amino]ethyl]amino]propoxy]methyl]-7,11-dioxa-3,15-diazaheptadecane-1,17-dyl]bis-, 2,2',3,3',4,4',5,5',6,6'-decaacetate (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN

TI Toward Iron Sensors: Bioinspired Tripods Based on Fluorescent Phenol-oxazoline Coordination Sites

AB In the quest for fast throughput metal biosensors, it would be of interest to prepare fluorophoric ligands with surface-adhesive moieties. Biomimetic analogs to microbial siderophores possessing such ligands offer attractive model compds. and new opportunities to meet this challenge. The design, synthesis, and physicochem. characterization of biomimetic analogs of microbial siderophores from Paracoccus denitrificans and from the Vibrio genus are described. The (4S,5S)-2-(2-hydroxyphenyl)-5-methyl-4,5-dihydro-1,3-oxazole-4-carbonyl group (La), noted here as an HPO unit, was selected for its potential dual properties, serving as a selective iron(III) binder and simultaneously as a fluorophore. Three tripodal sym. analogs cis-Lb, cis-Lc, and trans-Lc, which mainly differ in the length of the spacers between the central carbon anchor and the ligating sites, were synthesized. These ferric-carriers were built from a tetrahedral carbon as an anchor, sym. extended by three converging iron-binding chains, each bearing a terminal HPO. The fourth chain could contain a surface-adhesive function (Lc). A combination of absorption and emission spectrophotometry, potentiometry, electrospray mass spectrometry, and electrochem. was used to fully characterize the corresponding ferric complexes and to determine their stability. The quenching mechanism is consistent with an intramol. static process and is more efficient for the analog with longer arms. Detection limits in the low nanogram per mL range, comparable with the best chemosensors based on natural peptide siderophores, have been determined These results clearly demonstrate that these tris(phenol-oxazoline) ligands in a tripodal arrangement firmly bind iron(III). Due to their fluorescent properties, the coordination event can be easily monitored, while the fourth arm is available for surface-adhesive moieties. The tripodal system is therefore an ideal candidate for integration with solid-state materials for the development of chip-based devices and anal. methodologies.

AN 2007:216788 CAPLUS <<LOGINID::20080731>>

DN 146:457805

TI Toward Iron Sensors: Bioinspired Tripods Based on Fluorescent Phenol-oxazoline Coordination Sites

AU Kikkeri, Raghavendra; Traboulsi, Hassan; Humbert, Nicolas; Gumienna-Kontecka, Elzbieta; Arad-Yellin, Rina; Melman, Galina; Elhabiri, Mourad; Albrecht-Gary, Anne-Marie; Shanzer, Abraham

CS Department of Organic Chemistry, The Weizmann Institute of Science, Rehovot, Israel

SO Inorganic Chemistry (Washington, DC, United States) (2007), 46(7), 2485-2497

CODEN: INOCAJ; ISSN: 0020-1669
PB American Chemical Society
DT Journal
LA English
OS CASREACT 146:457805
IT 934995-49-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(bioinspired tripods based on fluorescent phenol-oxazoline coordination sites as iron sensors)
RN 934995-49-0 CAPLUS
CN 4,8-Dioxa-12,15,18-triazanonadecanamide, 6-ethyl-17-[(1R)-1-hydroxyethyl]-6-[(11S)-11-[(1R)-1-hydroxyethyl]-5,10,13-trioxo-2-oxa-6,9,12-triazatridec-1-yl]-N-[2-[[(2S,3R)-3-hydroxy-1-oxo-2-[[2-(phenylmethoxy)benzoyl]amino]butyl]amino]ethyl]-11,16,19-trioxo-19-[2-(phenylmethoxy)phenyl]-, (17S)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RE.CNT 136 THERE ARE 136 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
TI Solution phase biopolymer synthesis of oligodeoxyribonucleotides using multifunctional liquid phase carriers
AB Multifunctional liquid phase carriers (LPCs) and methods of using LPCs for the preparation of biopolymers are provided. The LPCs are highly sym. compds. that possess more than two points of attachment for biopolymer synthesis. The LPCs have the formula Sp(X1)n, where Sp is a highly sym. moiety such that all X1 groups are equivalent X1 is a functional group that is suitable for biopolymer synthesis, including OH, SH, NH2, COOH and the like. Biopolymers that may be produced using the methods provided include oligonucleotides, peptides, protein nucleic acids (PNAs) and oligosaccharides. Analogs of the biopolymers may also be prepared using the methods. Thus decamer d(GACCGGCAGT) was prepared using multifunctional liquid phase carriers.
AN 1999:708779 CAPLUS <<LOGINID::20080731>>
DN 131:351620
TI Solution phase biopolymer synthesis of oligodeoxyribonucleotides using multifunctional liquid phase carriers
IN Koster, Hubert; Worl, Ralf
PA USA
SO PCT Int. Appl., 88 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9955718	A2	19991104	WO 1999-US8939	19990426
	WO 9955718	A3	19991216		
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 20020016451	A1	20020207	US 1998-67337	19980427
	US 7094943	B2	20060822		
	AU 9936643	A	19991116	AU 1999-36643	19990426
	EP 1073668	A2	20010207	EP 1999-918819	19990426
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	US 20020007048	A1	20020117	US 2000-484484	20000118
	US 7038103	B2	20060502		
PRAI	US 1998-67337	A	19980427		
	WO 1999-US8939	W	19990426		

IT 221898-81-3P 221898-82-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(solution phase biopolymer synthesis of oligodeoxyribonucleotides using multifunctional liquid phase carriers)
RN 221898-81-3 CAPLUS
CN Thymidine, 5'-O-[bis(4-methoxyphenyl)phenylmethyl]-, 3',3'''-[14,14-[[3-[[2-[(3-carboxy-1-oxopropyl)amino]ethyl]amino]-3-oxopropoxy]methyl]-4,9,19,24-tetraoxo-12,16-dioxa-5,8,20,23-tetraazaheptacosanedioate], 3',3'''-diester with 5'-O-[bis(4-methoxyphenyl)phenylmethyl]thymidine (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 2-A



PAGE 2-B



PAGE 2-C



RN 221898-82-4 CAPLUS
CN Thymidine, 3',3'''-[14,14-[[3-[[2-[(3-carboxy-1-oxopropyl)amino]ethyl]amino]-3-oxopropoxy]methyl]-4,9,19,24-tetraoxo-12,16-dioxa-5,8,20,23-tetraazaheptacosanedioate], 3',3'''-diester with thymidine (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C

PAGE 2-A



PAGE 2-B

L13 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN

TI Synthesis of new liquid phase carriers for use in large scale oligodeoxyribonucleotide synthesis in solution

GI



I

AB The synthesis of multifunctional sym. primary amines, e.g. I, and the covalent binding of 5'-O-dimethoxytrityl-deoxynucleoside derivs. to their amino groups is described. Different strategies for dedimethoxytritylation including the use of strong acidic ion exchangers or protic acids and modified silica gels and/or gel permeation chromatog. are developed. The resulting liquid phase carriers are suitable for large scale oligodeoxyribonucleotide synthesis in solution using phosphoramidites and gel permeation chromatog. for fast isolation of intermediates.

AN 1999:176579 CAPLUS <<LOGINID::20080731>>
DN 130:267701

TI Synthesis of new liquid phase carriers for use in large scale oligodeoxyribonucleotide synthesis in solution

AU Worl, Ralf; Koster, Hubert
CS Faculty of Chemistry, Department of Biochemistry and Molecular Biology, University of Hamburg, Hamburg, D-20146, Germany

SO Tetrahedron (1999), 55(10), 2941-2956
CODEN: TETRAB; ISSN: 0040-4020
PB Elsevier Science Ltd.
DT Journal
LA English

IT 221898-81-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis of new liquid phase carriers for use in large scale oligodeoxyribonucleotide synthesis in solution)

RN 221898-81-3 CAPLUS

CN Thymidine, 5'-O-[bis(4-methoxyphenyl)phenylmethyl]-, 3',3'''-[14,14-[[3-[[2-[(3-carboxy-1-oxopropyl)amino]ethyl]amino]-3-oxopropoxy]methyl]-4,9,19,24-tetraoxo-12,16-dioxa-5,8,20,23-tetraazaheptacosanedioate], 3',3'''-diester with 5'-O-[bis(4-methoxyphenyl)phenylmethyl]thymidine (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 2-A



PAGE 2-B



PAGE 2-C



IT 221898-82-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(synthesis of new liquid phase carriers for use in large scale oligodeoxyribonucleotide synthesis in solution)

RN 221898-82-4 CAPLUS
CN Thymidine, 3',3'''-[14,14-[[3-[[2-[(3-carboxy-1-oxopropyl)amino]ethyl]amino]-3-oxopropoxy]methyl]-4,9,19,24-tetraoxo-12,16-dioxa-5,8,20,23-tetraazaheptacosanedioate], 3',3'''-diester with thymidine (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C

PAGE 2-A



PAGE 2-B

RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
TI N-hydroxyamide-containing heterocycles. Part 5. Synthesis of novel hexadentate ligands composed of N-hydroxy-2(1H)-pyrazinone, aliphatic diamine, and 1,1,1-tris(carboxyethoxymethyl)ethane, and properties of their ferric complexes
GI



I

AB Novel hexadentate ligands I (n = 2, 4, 5, 6), containing N-hydroxy-2(1H)-pyrazinone connected to tricarboxylic acid by an aliphatic diamine through amide bonds were synthesized. UV-visible spectra of the 1:1 M mixts. of I and ferric ion in aqueous solution and the mole ratio plot strongly supported the formation of intramol. 1:1 ferric complexes. The relative stability consts. (log K 20.6-21.7) of the complexes were affected by the spacer length in a mol. Further, I showed higher Fe removal efficiency toward human transferrin than naturally occurring siderophore, desferrioxamine B.

AN 1995:956600 CAPLUS <<LOGINID::20080731>>

DN 124:157320

OREF 124:29003a

TI N-hydroxyamide-containing heterocycles. Part 5. Synthesis of novel hexadentate ligands composed of N-hydroxy-2(1H)-pyrazinone, aliphatic diamine, and 1,1,1-tris(carboxyethoxymethyl)ethane, and properties of their ferric complexes

AU Ohkanda, Junko; Katoh, Akira

CS Dep. Industrial Chem., Seikei Univ., Musashino, 180, Japan

SO Tetrahedron (1995), 51(47), 12995-3002
CODEN: TETRAB; ISSN: 0040-4020

PB Elsevier

DT Journal

LA English

IT 173414-90-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(for preparation of tris(((hydroxydimethyloxodihydropyrazyl)propanamide)alkylaminocarbonyl)ethyloxymethyl)ethanes)

RN 173414-90-9 CAPLUS

CN Pyrazinepropanamide, N,N'-[9-[[3-[[2-[[3-[3,4-dihydro-5,6-dimethyl-3-oxo-4-(phenylmethoxy)pyrazinyl]-1-oxopropyl]amino]ethyl]amino]-3-oxopropoxy]methyl]-9-methyl-4,14-dioxo-7,11-dioxa-3,15-diazaheptadecane-

1,17-diyl]bis[3,4-dihydro-5,6-dimethyl-3-oxo-4-(phenylmethoxy)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 2-B



IT 173414-94-3P
RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation and complexation with iron and removal for iron from human transferrin)

RN 173414-94-3 CAPLUS

CN Pyrazinepropanamide, N,N'-[9-[[3-[[2-[[3-(3,4-dihydro-4-hydroxy-5,6-dimethyl-3-oxopyrazinyl)-1-oxopropyl]amino]ethyl]amino]-3-oxopropoxy]methyl]-9-methyl-4,14-dioxo-7,11-dioxa-3,15-diazaheptadecane-1,17-diyl]bis[3,4-dihydro-4-hydroxy-5,6-dimethyl-3-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 2-B



=> d his

(FILE 'HOME' ENTERED AT 12:38:22 ON 31 JUL 2008)

FILE 'REGISTRY' ENTERED AT 12:38:29 ON 31 JUL 2008
L1 STRUCTURE UPLOADED
L2 1 S L1
L3 45 S L1 SSS FULL

FILE 'HCAPLUS' ENTERED AT 12:39:49 ON 31 JUL 2008

```
L4           41 S L3
L5       275759 S CONJUGAT? OR LINKER
L6           10 S L4 AND L5

     FILE 'REGISTRY' ENTERED AT 13:22:47 ON 31 JUL 2008
L7              STRUCTURE UPLOADED
L8              STRUCTURE UPLOADED
L9              STRUCTURE UPLOADED
L10             STRUCTURE UPLOADED
L11           1 S L10
L12          22 S L10 SSS FULL

     FILE 'CAPLUS' ENTERED AT 13:52:40 ON 31 JUL 2008
L13           5 S L12

=> log hold

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      27.73     419.67

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                      -4.00     -12.00

 SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 13:52:59 ON 31 JUL 2008

Connecting via Winsock to STN



Welcome to STN International!  Enter x:X

LOGINID:SSPTAEXO1623

PASSWORD:
 * * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'CAPLUS' AT 14:00:50 ON 31 JUL 2008
FILE 'CAPLUS' ENTERED AT 14:00:50 ON 31 JUL 2008
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      27.73     419.67

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                      -4.00     -12.00

=> file registry
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      28.69     420.63

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                      -4.00     -12.00

FILE 'REGISTRY' ENTERED AT 14:02:04 ON 31 JUL 2008
```

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 30 JUL 2008 HIGHEST RN 1037244-07-7
DICTIONARY FILE UPDATES: 30 JUL 2008 HIGHEST RN 1037244-07-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\STNEXP\Queries\10780447linker2.str



chain nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44
chain bonds :
1-2 1-38 2-9 2-10 3-4 3-37 4-8 4-11 5-6 5-37 6-7 6-12 7-13 7-35 8-15
8-36 9-17 9-31 13-14 14-21 15-16 16-20 17-18 18-19 19-24 19-32 20-23
20-33 21-22 21-34
22-27 22-30 23-26 23-29 24-25 24-28 37-44 38-39 38-43 39-40 39-41 41-42
43-44
exact/norm bonds :
2-9 2-10 4-8 4-11 6-7 6-12 19-24 20-23 21-22 22-27 23-26 24-25 38-39
39-40 39-41

exact bonds :
1-2 1-38 3-4 3-37 5-6 5-37 7-13 7-35 8-15 8-36 9-17 9-31 13-14 14-21
15-16 16-20 17-18 18-19 19-32 20-33 21-34 22-30 23-29 24-28 37-44 38-43
41-42 43-44

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS
18:CLASS 19:CLASS
20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS
28:CLASS 29:CLASS
30:CLASS 31:CLASS 32:CLASS 33:CLASS 34:CLASS 35:CLASS 36:CLASS 37:CLASS
38:CLASS 39:CLASS
40:CLASS 41:CLASS 42:CLASS 43:CLASS 44:CLASS

L14 STRUCTURE UPLOADED

=> d l14
L14 HAS NO ANSWERS
L14 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l14
SAMPLE SEARCH INITIATED 14:02:29 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 35 TO ITERATE

```
100.0% PROCESSED       35 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          346 TO     1054
PROJECTED ANSWERS:               0 TO        0

L15           0 SEA SSS SAM L14

=> s l14 sss full
FULL SEARCH INITIATED 14:02:34 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      682 TO ITERATE

100.0% PROCESSED      682 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

L16           0 SEA SSS FUL L14
```